Hematocrit modulation through needle assisted jet injection of testosterone
AssigneeAntares Pharma, Inc.
InventorsPaul K. Wotton, Jonathan Jaffe
Life of this patent
Estimating the term…
Abstract
The present invention provides compositions and methods for treating a subject in need of treatment with testosterone, including introducing testosterone into the subject subcutaneously, intradermally, or intramuscularly, from a needle assisted jet injection device.
Claims17
A method of modulating or controlling the level of hematocrit in the blood of a subject, who is susceptible to a change in his or her hematocrit blood levels in response to a change in testosterone blood levels, comprising administering to the subject, in need of such a treatment, testosterone or a pharmaceutically acceptable ester or salt thereof, such that the maximum concentration of the testosterone or the pharmaceutically acceptable ester or salt thereof in the blood (serum or plasma) of the subject, following administration of a dose of the testosterone or of the pharmaceutically acceptable ester or salt thereof to the subject (“Cmax”), is maintained at a value from about 300 ng/dl to about 1800 ng/dl.
Dependencies are inferred from the claim text.